Clinical trials: Tuberculosis (TB)
Tuberculosis, HIV/AIDS
TB Reduction Through ART and TB Screening Project
Tuberculosis (TB) has overtaken HIV as the leading infectious cause of death worldwide and requires a major policy shift for it to be controlled in line with the WHO Stop-TB goal to "end TB".
- Trial name
- TREATS (NCT03739736)
- Testing
- Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Pulmonary TB
Comparison Between Two Strategies for the Diagnosis of TB
Tuberculosis (TB) is a major cause of death among the "communicable" diseases in the world. Pulmonary TB, the main localization, leads to the dissemination of cases.
- Trial name
- NCT02961569
- Testing
- sputum collection for acid fast bacilli
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Hopital Lariboisière
Safety, Immunogenicity
EMaBS TB Vaccine Study
The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents from the previous Entebbe Mother and Baby Study (EMaBS) in Entebbe, Uganda, focusing on ChAdOx1 85A, to provide safety…
- Trial name
- NCT03681860
- Testing
- ChAdOx185A, MVA85A, BCG
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, TPT
Systems Analysis and Improvement Approach to Prevent TB
This randomized trial uses the evidence-based Systems Analysis and Improvement Approach (SAIA) adapted for tuberculosis (SAIA-TB) to assess the comprehensive tuberculosis (TB) care cascade across 16 clinics in rural Eastern Cape…
- Conditions
- Tuberculosis, TPT, TB - Tuberculosis
- Trial name
- SAIA-TB (NCT06314386)
- Testing
- Systems Analysis and Improvement Approach for TB (SAIA-TB)
- Where
- 16 sites in South Africa
- Volunteers
- 19,560 people
- Sponsor
- Boston College
Tuberculosis, Pulmonary
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
The performance of a new triage test for active tuberculosis (TB), SeroSelectTB, will be qualified in multi-centre randomised controlled trials at health-posts in South Africa, Tanzania and Ethiopia.
- Trial name
- SeroSelectTB (NCT04752592)
- Testing
- SeroSelectTB rapid TB test
- Where
- 3 sites in Ethiopia, South Africa and 1 more
- Volunteers
- 9,097 people
- Sponsor
- Norwegian Institute of Public Health
Tuberculosis
Chepetsa TB - Reducing TB Among HIV-Infected Malawians
The specific aims of this project are: (1) to compare the impact of using the routine screening and GeneXpert algorithms for TB case detection on Tuberculosis (TB)- and HIV-related outcomes; (2) to compare the impact of using the…
- Trial name
- NCT01450085
- Testing
- GeneXpert, LED Microscopy
- Where
- 2 sites in Malawi
- Volunteers
- 1,200 people
- Sponsor
- Johns Hopkins University
Tuberculosis, HIV Infections
A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection
The purpose of this study is to determine if 30-day survival will be improved with addition of prednisone to standard tuberculosis (TB) therapy.
- Trial name
- NCT00414414
- Testing
- Prednisone
- Where
- 2 sites in Canada, South Africa
- Sponsor
- Ottawa Hospital Research Institute
Tuberculosis
A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
The purpose of this study is to determine whether a subunit tuberculosis vaccine given as two nasal immunizations composed of a hybrid protein antigen from M.
- Trial name
- TMUVA-01 (NCT00440544)
- Testing
- Ag85B-ESAT6 fusion protein H1
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Tuberculosis in Children
Impact of an Innovative Childhood TB Diagnostic Approach Decentralized to District Hospital and Primary Health Care Levels on Childhood Tuberculosis Case Detection and Management in High Tuberculosis Incidence Countries (TB-Speed Decentralisation)
The TB-Speed Decentralisation study aims to increase childhood Tuberculosis (TB) case detection at district hospital (DH) and Primary health Care (PHC) levels using adapted and child-friendly specimen collection methods, i.e.
- Trial name
- NCT04038632
- Testing
- Decentralization of Childhood TB Diagnosis
- Where
- 59 sites in Cambodia, Cameroon and 4 more
- Volunteers
- 3,106 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Tuberculosis
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
Novel approaches to improve TB treatment outcomes (to reduce morbidity, mortality, and the duration of TB treatment) and to treat XDR-TB cases are urgently required.
- Trial name
- NSAIDS-XDRTB (NCT02781909)
- Testing
- Ibuprofen, Standard of Care TB treatment
- Where
- 2 sites in Georgia, South Africa
- Volunteers
- 24 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Tuberculosis
Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity
Boost vaccinations sometimes have no effect because the body has got used to the vaccine and no longer reacts to it. We are therefore investigating whether vaccinating with aerosolised MVA85A (a candidate tuberculosis vaccine)…
- Trial name
- NCT01954563
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV
This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.
- Trial name
- NCT00731471
- Testing
- MVA85A
- Where
- Senegal
- Volunteers
- 24 people
- Sponsor
- University of Oxford
HIV Seropositivity, Pregnancy
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Open-label, two-arm, randomized multicenter study to investigate the safety, tolerability, and pharmacokinetics (PK), and potential interactions between dolutegravir (DTG) and rifapentine (RPT) during pregnancy in people with HIV…
- Conditions
- HIV Seropositivity, Pregnancy, Tuberculosis Infection
- Trial name
- DOLPHIN Moms (NCT05122026)
- Testing
- Rifapentine, Isoniazid
- Where
- 3 sites in South Africa
- Volunteers
- 252 people
- Sponsor
- The Aurum Institute NPC
HIV Infections, Tuberculosis
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa
The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection.
- Trial name
- NCT00640887
- Testing
- rifabutin in combination with efavirenz, rifabutin in combination with nevirapine, rifabutin in combination with lopinavir/ritonavir
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis
Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial
Tuberculosis increases energy demands and protein breakdown, leading to muscle wasting. Malnutrition and minimal weight gain less than 5% in first two months predict treatment failure.
- Conditions
- Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis, Pre-xdr tb
- Trial name
- NCT07058233
- Testing
- Oral nutritional supplementation
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- RSUP Persahabatan
Latent Tuberculosis
Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging
The purpose of this pilot study is to determine whether regularly scheduled medication reminder text messages (SMS) are effective in increasing latent tuberculosis infection (LTBI) treatment completion.
- Trial name
- TXT4MED (NCT02690818)
- Testing
- Regularly scheduled LTBI medication reminder text messages
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Tuberculosis Prevention, HIV
Kulindana: Community-friendly Delivery and Monitoring of TPT to Improve Uptake and Reduce TB Transmission
The goal of this clinical trial is to learn if differentiated service delivery (DSD) of TB preventive therapy (TPT) improves uptake and completion of TPT in two populations: household contacts (HHC) of index TB patients and…
- Trial name
- NCT07628140
- Testing
- Differentiated service delivery (DSD) of TB preventive therapy (TPT)
- Where
- Kenya
- Volunteers
- 1,500 people
- Sponsor
- University of Washington
Malignant Neoplasms, Tuberculosis (TB)
Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases
This interventional study evaluated the efficacy of Naderin (sodium nucleinate) for the prophylaxis of complications during basic therapy and medical rehabilitation in patients with socially significant diseases, including…
- Conditions
- Malignant Neoplasms, Tuberculosis (TB), HEPATITIS C (HCV)
- Trial name
- NADERIN-SSD (NCT07671508)
- Testing
- Naderin, Standard Therapy
- Volunteers
- 75 people
- Sponsor
- MIPO Clinic
Tuberculosis
Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
Despite marked improvements in the diagnosis of tuberculosis there are difficulties in diagnosing and monitoring treatment outcome among TB patients.
- Trial name
- LILAC-TB (NCT04015713)
- Where
- 2 sites in Cambodia, Côte d’Ivoire
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, Pulmonary
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin…
- Trial name
- NCT06714513
- Testing
- QTP101
- Where
- 4 sites in South Korea
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.